MindBio Therapeutics Reports Sustained Antidepressant Response from MB22001 in Depression Clinical Trials

MindBio Therapeutics Corp. has shared promising results from its Phase 2A clinical trials, highlighting a sustained antidepressant response from their drug MB22001, a microdose of Lysergic Acid Diethylamide (LSD). One month after treatment, patients experienced a 65% reduction in depressive symptoms.

The trial confirmed the safety, adherence, and tolerance of MB22001, echoing findings from previous Phase 1 trials. MindBio remains the only organization to run multiple Phase 2B clinical trials with regulatory approval for take-home microdoses of psychedelic medicine.

The company's innovative approach allows patients to self-administer sub-hallucinogenic doses at home, offering a viable alternative to more traditional and costlier hallucinogenic treatments typically performed in clinical settings.

MindBio has expanded its trials to include patients with depression, cancer, and more recently, Pre-Menstrual Syndrome (PMS) and Pre-Menstrual Dysphoric Disorder (PMDD). According to CEO Justin Hanka, these findings are a step forward in the commercialization of MB22001.